pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Prognostic factors of overall survival (OS)
Variables | Univariate analysis (Log rank test) | Multivariable analysis (Cox proportional hazard model) | ||||
---|---|---|---|---|---|---|
Number of patients (Progressed/Total) | Median PFS (months) | Log-rank |
HR | 95% CI | ||
Age, years | ||||||
<65 ≥65 |
59/93 49/63 |
17.50 13.30 |
0.026 | 3.40 | 1.05–11.04 | 0.042 |
Sex | ||||||
Male Female |
87/121 21/35 |
15.63 17.27 |
0.259 | |||
KPSa | ||||||
<80% ≥80% |
12/12 66/108 |
3.27 17.50 |
<0.001 | 4.11 | 1.27–13.35 | 0.019 |
Nephrectomy | ||||||
Yes No |
90/135 18/21 |
17.43 8.23 |
0.026 | |||
Histology | ||||||
Non-clear cell Clear cell |
6/8 102/148 |
9.70 16.80 |
0.326 | |||
Prior therapy | ||||||
Yes No |
26/41 82/115 |
18.03 14.60 |
0.108 | |||
Time from diagnosis to systemic treatment | ||||||
<1 year ≥1 years |
73/94 36/61 |
11.37 31.23 |
<0.001 | 4.43 | 1.71–11.47 | 0.002 |
Number of metastases | ||||||
1 ≥2 |
40/-60 68/96 |
25.80 9.70 |
0.033 | |||
Anemia | ||||||
Yes No |
69/87 39/69 |
11.37 25.80 |
0.003 | |||
Thrombosis | ||||||
Yes No |
9/16 99/140 |
11.83 16.80 |
0.983 | |||
Neutrophilia | ||||||
Yes No |
8/10 100/146 |
5.83 17.27 |
0.194 | |||
Hypercalcemia | ||||||
Yes No |
16/18 92/138 |
4.67 17.50 |
<0.001 | 5.34 | 1.53–18.65 | 0.009 |
Elevated LDH | ||||||
Yes No |
2/4 50/75 |
6.90 13.77 |
0.649 | |||
Pre-treatment NLR | ||||||
≥3 >3 |
71/113 37/43 |
18.43 7.47 |
<0.001 | |||
Sunitinib-induced hypothyroidism | ||||||
Overt Subclinical Euthyroid |
25/51 24/35 59/70 |
38.27 9.70 12.60 |
<0.001 | 0.23 | 0.09–0.64 | 0.005 |
Sunitinib-induced hypertension | ||||||
Yes No |
25/48 83/108 |
32.13 12.60 |
<0.001 | |||
Sunitinib-induced proteinuria | ||||||
Yes No |
38/63 70/93 |
21.30 13.30 |
0.049 | |||
Sunitinib-induced renal insufficiency | ||||||
Yes No |
15/23 93/133 |
23.50 14.93 |
0.121 |
CI: confidence interval, HR: hazard ratio, KPS: Karnofsky performance score, LDH: lactate dehydrogenase, NLR: neutrophil lymphocyte ratio, OS: overall survival
a)Evaluated in 120 patients, b)Evaluated in 79 patients